

# Hepatitis C: State of Medicaid Access Report Card

## Louisiana



Grade	Recommendations to Improve Patient Access
<b>A</b>	<ul style="list-style-type: none"> <li>Remove requirement for submission of chronic hepatitis C diagnosis code.</li> <li>Continue to ensure broad access to HCV treatment.</li> </ul>

### State Overview

As of September 2022, 1,868,642 individuals were enrolled in Medicaid and CHIP.<sup>1</sup> It is estimated that as of 2016, 50,000 people were living with HCV in Louisiana.<sup>2</sup> Louisiana Medicaid, known as Healthy Louisiana, operates a fee-for-service (FFS) program and contracts with managed care organizations (MCOs).<sup>3</sup> Most beneficiaries, 91 percent, are enrolled in a MCO; the remaining 9 percent participate in FFS.<sup>4</sup> Healthy Louisiana contracts with six MCOs to provide services to beneficiaries, including: Aetna Better Health (Aetna), AmeriHealth Caritas Louisiana (AmeriHealth), Healthy Blue, Humana Healthy Horizons, Louisiana Healthcare Connections, and UnitedHealthcare Community Plan (UHC).<sup>5</sup> As a result of the modified pharmaceutical subscription model for HCV treatment, all MCOs follow the Louisiana single PDL and criteria.<sup>6</sup>

The Louisiana Medicaid Preferred Drug List lists sofosbuvir/velpatasvir (generic Epclusa) as the preferred regimen.<sup>7</sup>

Deductions		Policy						
Prior Authorization		Prior authorization is not required for the preferred regimen (sofosbuvir/velpatasvir). <sup>8</sup>						
Fibrosis Restrictions		Louisiana Medicaid does not impose fibrosis restrictions. <sup>9</sup>						
Substance Use Restrictions		Louisiana Medicaid does not impose substance use restrictions. <sup>10</sup>						
Prescriber Restrictions		Louisiana Medicaid does not impose prescriber restrictions. <sup>11</sup>						
Retreatment Restrictions		Louisiana Medicaid does not impose undue retreatment restrictions. <sup>12</sup>						
Access in Managed Care		As a result of the modified pharmaceutical subscription model for HCV treatment, all MCOs follow the Louisiana single PDL and criteria. <sup>13</sup>						
Additional Restrictions	-2	Louisiana Medicaid imposes additional restrictions for preferred treatment: <sup>14</sup> <ul style="list-style-type: none"> <li>Documentation of chronic HCV infection. Pharmacy claims for all agents (including sofosbuvir/velpatasvir) must be submitted with the diagnosis code for chronic hepatitis C.<sup>15</sup> Eligibility is verified via a point-of-sale edit. Point of sale edits are “safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy.”<sup>16</sup></li> </ul>						
<b>Total Deductions</b>	<b>-2</b>	<table border="1" style="width: 100%;"> <tr> <td style="text-align: center;"><b>Total Score [100-Deductions]</b></td> <td style="text-align: center;"><b>98</b></td> <td style="text-align: center;"><b>Grade</b></td> </tr> <tr> <td></td> <td></td> <td style="text-align: center;"><b>A</b></td> </tr> </table>	<b>Total Score [100-Deductions]</b>	<b>98</b>	<b>Grade</b>			<b>A</b>
<b>Total Score [100-Deductions]</b>	<b>98</b>	<b>Grade</b>						
		<b>A</b>						

### Contact Your State Officials

**Medicaid Office**<sup>17</sup>: Tara Leblanc, Medicaid Director  
 Email Address: tara.leblanc@la.gov

**Pharmacy & Therapeutics Committee**<sup>18</sup>: Medicaid Pharmaceutical & Therapeutics Committee, Louisiana Department of Health  
 P. O. Box 91030, Baton Rouge, LA 70821; Telephone: (225) 342-7878; Email Address: healthy@la.gov

## Key Sources

---

**Preferred Drug List:** [Louisiana Medicaid, Preferred Drug List \(Jan. 1, 2023\)](#)

**Clinical Criteria:** [Louisiana Medicaid, Hepatitis C Direct Acting Antiviral Criteria \(Apr. 2022\)](#)

**Prior Authorization Form (for Non-Preferred DAAs):** [Louisiana Medicaid, DAA Medication Therapy Worksheet \(May 2019\)](#)

**Patient Treatment Agreement (for Non-Preferred DAAs):** [Louisiana Treatment Agreement for Louisiana Medicaid Recipients \(May 2019\)](#)

---

<sup>1</sup> Centers for Medicare & Medicaid Services, Medicaid & CHIP in Louisiana, <https://perma.cc/6E2Z-V3SS>.

<sup>2</sup> HepVu, Local Data: Louisiana: <https://perma.cc/85GV-9WX8>.

<sup>3</sup> Louisiana Department of Health, Healthy Louisiana: <https://perma.cc/82WX-LG99>.

<sup>4</sup> Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2022), <https://perma.cc/EMN8-QR8B>.

<sup>5</sup> Healthy Louisiana, Compare Plans: <https://perma.cc/WGB8-RFG9>.

<sup>6</sup> Preferred Drug List; see also Louisiana Department of Health, Managed Care Executed Contracts, <https://perma.cc/7T5U-ERFC>.

<sup>7</sup> Preferred Drug List.

<sup>8</sup> Clinical Criteria.

<sup>9</sup> Clinical Criteria.

<sup>10</sup> Clinical Criteria.

<sup>11</sup> Clinical Criteria.

<sup>12</sup> Clinical Criteria.

<sup>13</sup> Preferred Drug List; see also Louisiana Department of Health, Managed Care Executed Contracts, <https://perma.cc/7T5U-ERFC>.

<sup>14</sup> Clinical Criteria.

<sup>15</sup> Louisiana Medicaid, Point of Sale Edits: Infectious Disorders – Hepatitis C Agents – Direct Acting Antiviral Agents (October 2022), <https://perma.cc/5VP5-JTAK>; see also Louisiana Medicaid, Medications Requiring ICD-10 Diagnosis Codes (Jan. 2023), <https://perma.cc/5UTG-SK47>.

<sup>16</sup> Louisiana Medicaid, Point of Sale Edits: Infectious Disorders – Hepatitis C Agents – Direct Acting Antiviral Agents (October 2022), <https://perma.cc/5VP5-JTAK>.

<sup>17</sup> National Association of Medicaid Directors, Medicaid Directors: <https://perma.cc/RK6K-TFKK>.

<sup>18</sup> Louisiana Department of Health, Medicaid Pharmaceutical & Therapeutics Committee, <https://perma.cc/2H67-ZWJ4>.